Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study

Journal of Clinical Hypertension

Volumn 18, Issue 6, 2016, Pages 543-550

  Verheyen, Nicolas D ^a   Kienreich, Katharina ^a   Gaksch, Martin ^a   van Ballegooijen, Adriana J ^b   Grübler, Martin R ^a   Hartaigh, Briain Ó ^c,d   Schmid, Johannes ^a   Fahrleitner Pammer, Astrid ^a   Kraigher Krainer, Elisabeth ^e   Colantonio, Caterina ^a   Belyavskiy, Evgeny ^e   Treiber, Gerlies ^a   Catena, Cristiana ^a   Brussee, Helmut ^a   Pieske, Burkert ^a,e   März, Winfried ^f,g,h   Tomaschitz, Andreas ^a,e,i   Pilz, Stefan ^a,j  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF UDINE   (Italy)

^g SYNLAB ACADEMY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ Specialist Clinic for Rehabilitation   (Austria)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PARATHYROID HORMONE;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NOCTURNAL BLOOD PRESSURE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 84975504443     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12710     Document Type: Article

References (36)

1. Sytkowski PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation. 1996;93:697–703.
2. McCarron DA, Pingree PA, Rubin RJ, et al. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension. 1980;2:162–168.
3. Lafferty FW. Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests. Arch Intern Med. 1981;141:1761–1766.
4. Letizia C, Ferrari P, Cotesta D, et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens. 2005;19:901–906.
5. Kanbay M, Isik B, Akcay A, et al. Relation between serum calcium, phosphate, parathyroid hormone and ‘nondipper’ circadian blood pressure variability profile in patients with normal renal function. Am J Nephrol. 2007;27:516–521.
6. Jubiz W, Canterbury JM, Reiss E, Tyler FH. Circadian rhythm in serum parathyroid hormone concentration in human subjects: correlation with serum calcium, phosphate, albumin, and growth hormone levels. J Clin Invest. 1972;51:2040–2046.
7. Fraser WD. Hyperparathyroidism. Lancet. 2009;374:145–158.
8. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metab, Clin Exp. 2014;63:20–31.
9. van Ballegooijen AJ, Visser M, Cotch MF, et al. Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGES-Reykjavik. J Clin Endocrinol Metab. 2013;98:2544–2552.
10. Hagström E, Ingelsson E, Sundström J, et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12:1186–1192.
11. Hagström E, Michaëlsson K, Melhus H, et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-Based Cohorts. Arterioscler Thromb Vasc Biol. 2014;34:1567–1573.
12. van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA. Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J. 2013;165:655–664, 664.e1–5.
13. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant. 1997;12:933–938.
14. van Ballegooijen AJ, Kestenbaum B, Sachs MC, et al. Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63:1214–1222.
15. Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens. 2008;26:1390–1394.
16. Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens. 2005;23:1639–1644.
17. Norenstedt S, Pernow Y, Brismar K, et al. Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur J Endocrinol. 2013;169:795–804.
18. Grübler MR, Kienreich K, Gaksch M, et al. Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the styrian hypertension study. J Clin Hypertens (Greenwich). 2014;16:289–294.
19. O HB, Gaksch M, Kienreich K, et al. Associations of daytime, nighttime, and 24-hour heart rate with four distinct markers of inflammation in hypertensive patients: the styrian hypertension study. J Clin Hypertens (Greenwich) 2014;16:856–861.
20. Eastell R, Brandi ML, Costa AG, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014;99:3570–3579.
21. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–1768.
22. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219.
23. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–161.
24. Altay H, Zorlu A, Binici S, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012;109:252–256.
25. Witham MD, Ireland S, Houston JG, et al. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in resistant hypertension: randomized, controlled trial. Hypertension. 2014;63:706–712.
26. Witham MD, Price RJG, Struthers AD, et al. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Intern Med. 2013;173:1672–1679.
27. Hulter HN, Melby JC, Peterson JC, Cooke CR. Chronic continuous PTH infusion results in hypertension in normal subjects. J Clin Hypertens (Greenwich). 1986;2:360–370.
28. Bosworth C, Sachs MC, Duprez D, et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol (Oxf). 2013;79:429–436.
29. Brown J, de Boer IH, Robinson-Cohen C, et al. Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis. J Clin Endocrinol Metab. 2015;100:490–499.
30. Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens. 1997;15:1271–1276.
31. Rydberg E, Birgander M, Bondeson A, et al. Effect of successful parathyroidectomy on 24-hour ambulatory blood pressure in patients with primary hyperparathyroidism. Int J Cardiol. 2010;142:15–21.
32. Tomaschitz A, Fahrleitner-Pammer A, Pieske B, et al. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord. 2012;13:19.
33. Tomaschitz A, Pilz S, Rus-Machan J, et al. Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. Int J Cardiol. 2015;184:710–716.
34. Brown JM, Williams JS, Luther JM, et al. Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension. 2014;63:273–280.
35. Loncar G, Bozic B, Dimkovic S, et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. J Endocrinol Invest. 2011;34:e78–e85.
36. Rutledge MR, Farah V, Adeboye AA, et al. Parathyroid hormone, a crucial mediator of pathologic cardiac remodeling in aldosteronism. Cardiovasc Drugs Ther. 2013;27:161–170.